Zepp Health (ZEPP) CTO Meihui Fan Buys 520,000 Shares

Meihui Fan, the Chief Technology Officer of Zepp Health Corporation, recently acquired 520,000 shares of the company. This transaction took place on June 26, 2026, and was not part of a pre-planned trading program.

Insider Buying and Selling at Zepp Health Corporation

On June 26, 2026, Meihui Fan, Zepp Health's CTO, bought 520,000 shares, which was not under a Rule 10b5-1 plan. Additionally, the company's CFO, Cheng Deng, was active with transactions on the same day, buying 22,875 shares and selling 9,836 shares at an average price of $4.61.

Other Institutional Activity in Zepp Health

Several institutional investors have made changes to their positions in Zepp Health. FIL LTD increased its holdings by 91,596 shares, bringing its total to 717,352 shares valued at approximately $8.57 million, a 14.6% increase. Morgan Stanley also grew its stake by 97,397 shares to 707,691 shares, worth about $8.46 million, marking a 16.0% increase. Point72 Asset Management, however, slightly reduced its holdings by 294 shares, now holding 577,676 shares valued at $6.90 million. Meanwhile, Millennium Management decreased its position by 24,322 shares to 342,504 shares, valued at $4.09 million, a 6.6% reduction.

Zepp Health Corporation Stock Up 9.5%

Shares of NYSE:ZEPP traded near $4.73 on Wednesday. Zepp Health Corporation has a market capitalization of $76.4 million and a forward P/E ratio of 74.4, indicating expectations of future profitability despite current losses. The stock has experienced a 52-week low of $2.56 and a high of $61.85. Its 50-day moving average stands at $10.06, while the 200-day moving average is $24.23. The company has a current ratio of 0.881 and a quick ratio of 0.39, with a debt-to-equity ratio of 66.1.

Recent Earnings

Zepp Health reported revenue of approximately $271.9 million, with a growth rate of 33.8%. Despite this growth, the company recorded a negative net margin of 14.7% and a return on equity of -18.8%. The company's next earnings report is anticipated on August 3, 2026.

Analysts Set New Price Targets

On August 21, 2023, Citi maintained its 'buy' rating for Zepp Health, setting a price target of $3.1. Currently, the consensus target price is $56.28, based on one analyst opinion.

About Zepp Health Corporation

Zepp Health Corporation is a technology company in the consumer electronics industry, headquartered in Gorinchem, Netherlands. It specializes in smart wearables and health technology, offering products like smart bands, watches, and rings under the Amazfit and Zepp brands in about 90 countries. Led by CEO Mr. Wang Huang, the company employs 763 people and focuses on enhancing health, fitness, and wellness through its innovative products.

Bottom Line

The insider purchase by Meihui Fan suggests confidence in Zepp Health's future prospects. Investors often keep a close eye on such transactions as potential indicators of the company's trajectory. However, it's important to remember that insider transactions are just one piece of the puzzle, and this information reflects past actions, not current positions.